Roche to Invest USD 50 Bn in US Pharma & Diagnostics Over Five Years

The company confirmed the plan on April 22, highlighting its intention to enhance its manufacturing and research operations across multiple US states.

Roche has announced a USD 50 billion investment in the United States over the next five years to expand its pharmaceutical and diagnostics infrastructure.

The company confirmed the plan on April 22, highlighting its intention to enhance its manufacturing and research operations across multiple US states.

This investment is expected to create over 12,000 new jobs, including 6,500 in construction and around 1,000 positions across new and expanded facilities. Roche currently employs over 25,000 people at 24 sites across eight states in the US.

The planned expansion will significantly increase its presence in the pharmaceutical and diagnostics sectors.

Key Infrastructure Developments and Research Focus

According to the company, the USD 50 billion commitment will fund the development and enhancement of several facilities, including:

• Expanded manufacturing and distribution capacities in Kentucky, Indiana, New Jersey, Oregon, and California.

• A new gene therapy manufacturing site in Pennsylvania.

• A 900,000 sq. ft. facility dedicated to weight loss drug production, with the location yet to be announced.

• A new manufacturing unit for continuous glucose monitoring devices in Indiana.

• An AI-focused research and development center in Massachusetts will also support research in cardiovascular, renal, and metabolic health.

• Upgrades to existing R&D sites in Arizona, Indiana, and California.

Thomas Schinecker, CEO of Roche Group, stated, “Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development, and manufacturing in the US.”

He further emphasized the strategic importance of the US market to Roche’s operations: “Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

Upon completing the proposed expansions, Roche expects its US operations to export more pharmaceuticals than they import. The diagnostics division already maintains a trade surplus from the US to other countries.

Founded in 1896 and headquartered in Basel, Switzerland, Roche remains one of the largest biotech companies globally, with a significant role in the development and delivery of diagnostics and pharmaceuticals.